Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07091526
Recruiting Observational

Whether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer

NCT07091526 · tracked via the Priya Life Science China tracker
Sponsor
Hepatopancreatobiliary Surgery Institute of Gansu Province
Phase
Observational
Started
2025-07-29
Last updated
2025-12-19

Condition(s) studied

Serum Uric Acid

Investigational drug(s) / intervention(s)

serum uric acid test

serum uric acid test: Detect the serum uric acid in blood sample

Study summary

This retrospective study aims to analyze the impact of postoperative changes in serum uric acid (SUA) levels on the prognosis of patients undergoing pancreatic cancer resection.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Patients with pathologically confirmed pancreatic cancer (primary) * Patients who underwent Radical resection of pancreatic cancer（Pancreaticoduodenectomy or Distal pancreatectomy） * The postoperative survival time was at least 6 weeks Exclusion Criteria: * No surgery was performed, or only palliative surgery/ biopsy was performed * Patients who underwent emergency hemodialysis or plasma exchange after surgery * History of gout or long-term urate-lowering therapy, such as allopurinol * Patients are missing follow-up data * Hydrochlorothiazide and furosemide were used * Chronic kidney disease * Oncolytic syndrome * Hemolytic anemia * Lead poisoning * Hyperparathyroidism * Hypothyroidism * A tyrosinase inhibitor was used * Patients with nonpancreatic primary tumors * Pregnant or postpartum women.

Primary outcome measure(s)

  • Overall survival — 3-5 years
    Overall survival was defined as the time from diagnosis to death.

Trial sites (1)

FacilityCityRegionStatus
Hepatopancreatobiliary Surgery Institute of Gansu Province Lanzhou Gansu Recruiting

More Hepatopancreatobiliary Surgery Institute of Gansu Province trials in China

A Strategy for Gallstone Expulsion Through Dietary Therapy Recruiting
Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma Starting soon
Bao Yuan Tang Extract and Galactooligosaccharides for Sleep Regulation Starting soon
The Optimal Measurement Time for the New Gallbladder Function Assessment Method Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07091526 on ClinicalTrials.gov ↗ ← All trials in China